19 - References

References

20 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Royal College of Psychiatrists. The Risks and Benefits of High-­Dose Antipsychotic Medication. College Report CR190. London: Royal College of Psychiatrists; 2014.
2. Paton C, et al. High-­dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008; 192:435–439.
3. Roh D, et al. Antipsychotic polypharmacy and high-­dose prescription in schizophrenia: a 5-­year comparison. Aust N Z J Psychiatry 2014; 48:52–60.
4. Campos Mendes J, et al. Patterns of antipsychotics’ prescription in Portuguese acute psychiatric wards: a cross-­sectional study. Psychiatry Res 2016; 246:142–148.
5. Martinho S, et al. Antipsychotic polypharmacy and high-­dose antipsychotics in involuntary patients: a seven-­year audit of discharge prescriptions in an acute care unit. Psychiatr Q 2021; 92:1–14.
6. Kaikoushi K, et al. Prescription patterns in psychiatric compulsory care: polypharmacy and high-­dose antipsychotics. BJPsych Open 2021; 7:e149.
7. Patel MX, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol 2014; 24:499–509.
8. Royal College of Psychiatrists. Prescribing Observatory for Mental Health. Topic 1h & 3e: Prescribing of antipsychotic medication in adult mental health services, including high dose, combined, and PRN. CCQI 422. 2022 (last accessed February 2025); https://www.rcpsych.ac.uk/ improving-­care/ccqi/national-­clinical-­audits/pomh.
9. Davis JM, et al. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24:192–208.
10. Gardner DM, et al. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167:686–693.
11. Ezewuzie N, et al. Establishing a dose-­response relationship for oral risperidone in relapsed schizophrenia. J Psychopharm 2006; 20:86–90.
12. Sparshatt A, et al. Quetiapine: dose–response relationship in schizophrenia. CNS Drugs 2008; 22:49–68.
13. Kinon BJ, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-­ blind, fixed-­dose study. J Clin Psychopharmacol 2008; 28:392–400.
14. Bishara D, et al. Olanzapine: a systematic review and meta-­regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 2013; 33:329–335.
15. Meltzer HY, et al. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr Res 2014; 154:14–22.
16. Goff DC, et al. High-­dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol 2013; 33:485–490.
17. Egerton A, et al. Dopamine and glutamate in antipsychotic-­responsive compared with antipsychotic-­nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA). Schizophr Bull 2021; 47:505–516.
18. Kapur S, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-­blind PET study of first-­episode schizophrenia. Am J Psychiatry 2000; 157:514–520.
19. Demjaha A, et al. Dopamine synthesis capacity in patients with treatment-­resistant schizophrenia. Am J Psychiatry 2012; 169:1203–1210.
20. Gillespie AL, et al. Is treatment-­resistant schizophrenia categorically distinct from treatment-­responsive schizophrenia? A systematic review. BMC Psychiatry 2017; 17:12.
21. Dold M, et al. Dose escalation of antipsychotic drugs in schizophrenia: a meta-­analysis of randomized controlled trials. Schizophr Res 2015; 166:187–193.
22. Agid O, et al. An algorithm-­based approach to first-­episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72:1439–1444.
23. Aubree JC, et al. High and very high dosage antipsychotics: a critical review. J Clin Psychiatry 1980; 41:341–350.
24. Boggs DL, et al. Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res 2008; 101:347–348.
25. Meltzer HY, et al. A randomized, double-­blind comparison of clozapine and high-­dose olanzapine in treatment-­resistant patients with schizophrenia. J Clin Psychiatry 2008; 69:274–285.
26. Souza JS, et al. Efficacy of olanzapine in comparison with clozapine for treatment-­resistant schizophrenia: evidence from a systematic review and meta-­analyses. CNS Spectr 2013; 18:82–89.
27. Gannon L, et  al. High-­dose olanzapine in treatment-­resistant schizophrenia: a systematic review. Ther Adv Psychopharmacol 2023; 13:20451253231168788.
28. Leucht S, et al. Dose-­response meta-­analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 2020; 177:342–353.
29. Loebel A, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-­controlled study. J Clin Psychiatry 2016; 77:1672–1680.
30. McAdam MK, et al. Second International Consensus Study of Antipsychotic Dosing (ICSAD-­2). J Psychopharmacol 2023; 37:982–991.
31. Siafis S, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-­effects: a systematic review and dose-­response meta-­analysis. Mol Psychiatry 2023; 28:3267–3277.
32. Yoshida K, et  al. Dose-­dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behav Brain Res 2021; 402:113098.
33. Wu H, et  al. Antipsychotic-­induced weight gain: dose-­response meta-­analysis of randomized controlled trials. Schizophr Bull 2022; 48:643–654.
34. He L, et al. A real-­world study of risk factors for QTc prolongation in schizophrenia patients receiving atypical antipsychotics. J Clin Psychopharmacol 2022; 42:71–74.
35. Osborn DP, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Arch Gen Psychiatry 2007; 64:242–249.

Schizophrenia and related psychoses CHAPTER 1 36. Ray WA, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225–235. 37. Barbui C, et al. Antipsychotic dose mediates the association between polypharmacy and corrected QT interval. PLoS One 2016; 11:e0148212. 38. Weinmann S, et al. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009; 113:1–11. 39. Honer WG, et al. A randomized, double-­blind, placebo-­controlled study of the safety and tolerability of high-­dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012; 73:13–20. 40. Bollini P, et  al. Antipsychotic drugs: is more worse? A meta-­analysis of the published randomized control trials. Psychol Med 1994; 24:307–316. 41. Baldessarini RJ, et al. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45:79–90. 42. Kawai N, et  al. High-­dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-­reduction. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1009–1014.